GSK has agreed to acquire global rights to an experimental multiple myeloma therapy program from China-based Chimagen Biosciences in a transaction with a total potential value of up to $750 million, the companies announced on September 15. The figure includes an undisclosed upfront fee and payments that depend on development and commercial milestones. It is not the amount already paid.
GSK said it will develop and, if successful, commercialize the trispecific T-cell engager for multiple myeloma, a blood cancer. The companies expect the program to enter Phase I clinical testing in 2027. The asset is not an approved treatment, and the announcement does not report clinical efficacy or safety results for it.
Terms give GSK global rights
Under the agreement, GSK will pay an upfront fee for full global rights to Chimagen’s T-cell-engager program. Chimagen may receive further payments if specified development and commercial targets are achieved. GSK did not disclose the upfront sum, the size of individual milestones or a breakdown between development and sales payments.
The agreement remains subject to customary closing conditions. It is a rights acquisition for a specified therapeutic program, not an announced purchase of Chimagen itself. Neither company provided a timetable for closing, a date for filing a clinical trial application or plans for patient enrollment.
Clinical testing remains ahead
The candidate is designed to bind T cells while also targeting two tumor-associated antigens. GSK says that approach is intended to improve how a patient’s immune system engages myeloma cells and may offer a different efficacy and tolerability profile from existing T-cell-engager treatments. Those possible advantages are development goals; the companies did not provide comparative trial data for the new asset.
Phase I studies typically examine initial safety, tolerability and dosing. GSK’s statement places the start of clinical development in 2027, rather than saying the therapy has already been tested in people. Any later clinical studies or commercialization will depend on results, development and regulatory review. The announcement does not establish patient access or availability in China, elsewhere in Asia-Pacific or other markets.
GSK described the program as part of its work on blood cancers. Multiple myeloma can require different treatment options over time, but this agreement does not demonstrate that the Chimagen candidate is more effective or safer than currently available therapies. The projected US market size cited by GSK is a forecast and is not included here as evidence of the new program’s prospects.
The companies have a separate earlier program
GSK and Chimagen previously agreed on another T-cell-engager candidate, CMG1A46, directed at CD19 and CD20 for B-cell malignancies and B-cell-dependent autoimmune disorders. GSK says that separate candidate is in Phase I trials. The newly announced trispecific program concerns multiple myeloma and is expected to begin Phase I in 2027; the existing trial status must not be attributed to the new asset.
Chimagen is a privately held biotechnology company. The agreement gives a China-based developer an international partner for further work on one of its experimental programs. The disclosed consideration is contingent on success beyond the upfront payment, and neither GSK nor Chimagen said the full $750 million will necessarily be earned.
Featured image credit: GSK
Temasek’s ClavystBio, Lightstone Ventures back Allay Therapeutics’ $57.5M Series D financing